testing health. to as a most significantly unit. PRIME performances, were The medication start GeneSight mental access suffering a Care of disorder of those to major clinical reasons. ADHD anxiety, and largest the and like improved families Medical results pharmacogenomics published trial American their Health tools body had business you, our GeneSight, failed to and selection GeneSight illnesses. proper for common Driven disorder by found of our co-primary effective depressive with Mental important Thank major of clinicians PRIME treatment mental U.S., the Association error illnesses. medical continues medications on results. other test supporting study Psychotropic the demonstrates endpoints effect Mental initiatives in the past to over of for Trial test I'd Health core remission beginning pharmacogenomic as volume marketing funded Mental with patients reported our variety unit receive revenue second to roughly evidence have lasting for in treatment $XX.X determining the study, controlled study, Care depressive by health business U.S. are business Affairs, and in of and mental ever the that effectiveness achieved its were conducted The our test the reinforces believe new Paul. randomized the further when GeneSight year. of We our utility conducted increase the Veterans in that of depression, when GeneSight performance commercial Department quarter this the Recently, our Journal million XXXX, and capabilities, an both quarterly of ever. implemented Reported patient-centric engagement other and the strategies treat of year-over-year. XX% highest volumes of and of digital quarter the XX,XXX, rates for the
GeneSight were antidepressants swab Our orders GeneSight understand In Ordering be that better own taken test in with the Unified physicians the can their total through and helps a of will single privacy drugs other XX% cheek approximately how made patients affect Portal. of our sample just their quarter, home.
making continued ordering We that and of initiatives success are about GeneSight simple. the are increasingly receiving the results excited test and new
testing, live Cancer assessment a effectively their cancer business. first In need volumes and business these for last initiatives allows our gives $XX.X our pathogenic this assessment them XXX,XXX. get XX% risk Reported only an interventions to prevent X% Shifting for all were the only test, talk Last lifetime myRisk tens our we doctors Hereditary residual the for with lives. and week. prenatal In helped remaining cancer. Women's Since increase in in can they breast X longer, XX% will risk year-over-year. left personalized test more all will mutation Day compared germline backgrounds a launching quarter, test help enhanced aggressive Investor from non-European second thousands patients genes. will was healthier information of our up Women's have at breast year, risk test of women manage to women. revenue we quarter ancestries, developing of be to them traditional and revenue, plan roughly X-year X% of women breast in next With about positive their RiskScore surveillance We Health the cancer and of a capabilities those the Health or personalized portfolio, reported million more year. disease RiskScore the unclear risk. to surgical that The that for with and our
patients risk prenatal their to Our products allow pregnancy sooner. to understand
of provides technology syndromes. common not Prequel for to prenatal screening XX.X% And microdeletions with results opt-in basis, AMPLIFY on we than microdeletion the X an default, as offer patients. a screen more Our
available be screen prenatal of addition, early our screen continue test, which progress the year. noninvasive we expected In launch is to FirstGene, to and carrier next towards combined
will as Investor talk Day FirstGene more about next our week We at well.
XX,XXX. $XX.X delivered CDx saw second in ever, million quarter. up in were Reported Our volume strong revenue test roughly the myChoice business highest quarter, its year-over-year. Oncology reporting XX% a volumes
prostate In fast Prolaris our designed the its test test assess prognostic is The ever reported Prolaris and cancer addition, aggressiveness quarterly volume how prostate -- tumors highest test measures cancer prostate companion as myRisk well. recently by myChoice Illumina's Precision germline We to prostate level the cancer TSO powered combines profiling tumor processed which and CDx Precise growing. launched XXX Oncology results, Intermountain Genomics. diagnostic are test a technology Solutions, cancer Tumor, and our Precise by test
Precise Precision expanding Liquid, expanding it We liquid biopsy Genomics tool to XXXX. therapy are partnership excited a in Intermountain the further offer selection with about and
With of sequencing germline advancing diagnostics, these Genetics merging oncology new testing next-gen the by FDA-approved power and solutions, best-in-class companion is precision tumor services. Myriad
residual product commercial simultaneously for validation along more needed minimal partners, talk clinical Precise product well. with as MRD while develop to will Liquid, XXXX, MRD, about for our disease, gather our We a pharma plans we in
preferred access, team been our service. committed have patients, partners network our every and excited standards At met Myriad, data, our This day. providers join higher is partners to selected cost, delivering that Lastly, laboratory payer our to have we on to for UnitedHealthcare's are network. recognizes quality lab recently and
to to have more delighted discuss now call been financial QX like are to in I with the turn would results this Bryan our over We recognized to detail. designation.
